# Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

> **NCT02920021** · PHASE2 · COMPLETED · sponsor: **AnaptysBio, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Peanut Allergy

## Interventions

- **DRUG:** Etokimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02920021
- **Lead sponsor:** AnaptysBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-26
- **Primary completion:** 2018-03-30
- **Final completion:** 2018-03-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02920021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02920021, "Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02920021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*